Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 1
2007 2
2008 2
2009 1
2010 2
2011 2
2012 3
2014 1
2017 1
2018 3
2019 4
2020 6
2021 3
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
JAK1 inhibition and inflammatory bowel disease.
Harris C, Cummings JRF. Harris C, et al. Among authors: cummings jrf. Rheumatology (Oxford). 2021 May 5;60(Supple 2):ii45-ii51. doi: 10.1093/rheumatology/keaa896. Rheumatology (Oxford). 2021. PMID: 33950226 Free PMC article. Review.
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Kennedy NA, et al. Among authors: cummings jrf. Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27. Lancet Gastroenterol Hepatol. 2019. PMID: 30824404
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Irving PM, Barrett JC, McGovern D, Goodhand JR, Anderson CA, Ahmad T; PANTS Consortium. Sazonovs A, et al. Among authors: cummings jrf. Gastroenterology. 2020 Jan;158(1):189-199. doi: 10.1053/j.gastro.2019.09.041. Epub 2019 Oct 7. Gastroenterology. 2020. PMID: 31600487 Free article.
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review.
Corominas H, Young D, Cummings JRF, Bouhnik Y, Armuzzi A, Thaci D, Kim J. Corominas H, et al. Among authors: cummings jrf. Clin Drug Investig. 2023 Aug;43(8):579-593. doi: 10.1007/s40261-023-01284-5. Epub 2023 Aug 24. Clin Drug Investig. 2023. PMID: 37615857 Free PMC article. Review.
Medical management of Crohn's disease.
Cummings JR, Keshav S, Travis SP. Cummings JR, et al. BMJ. 2008 May 10;336(7652):1062-6. doi: 10.1136/bmj.39547.603218.AE. BMJ. 2008. PMID: 18467414 Free PMC article. Review. No abstract available.
Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial.
Brendish NJ, Beard KR, Malachira AK, Tanner AR, Sanga-Nyirongo L, Gwiggner M, Cummings JRF, Moyses HE, Clark TW. Brendish NJ, et al. Among authors: cummings jrf. Lancet Infect Dis. 2023 Aug;23(8):945-955. doi: 10.1016/S1473-3099(23)00066-X. Epub 2023 Apr 25. Lancet Infect Dis. 2023. PMID: 37116527 Free article. Clinical Trial.
40 results